Recombinant growth hormone replaces cadaver-derived hormone (1985)
The FDA approved Genentech's Protropin, the first growth hormone made in bacteria rather than extracted from human pituitary glands. The change followed reports of Creutzfeldt-Jakob disease in people who had received the pituitary-derived product.
Synthetic hormone replaced the cadaver-derived supply, removing infection risk and production limits.
Growth hormone became abundant and routine, shifting the burden of treatment from supply to the frequency of injections.
The problem Sogroya solves only exists because the drug itself became safe and plentiful. Competition moved to convenience.
